3,560 material Form 8-K filings that 2,489 companies we cover made with the SEC in October 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). 2,508 of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Charlton Aria Acquisition Corp notified Nasdaq that its audit committee did not meet a listing rule from at least August 25, 2026, because a director was indirectly paid $30,000 through an accounting firm he is a partner in. The board reconstituted the audit committee on October 22, 2026, and the company believes it regained compliance that day, with no Nasdaq notice received and its securities still listed.
Director Kyoung Tak Kim's firm, Leading Edge Advisory Inc., was paid $30,000, settled in full on August 25, 2026.
Audit committee was out of compliance from at least August 25, 2026, per the filing; the matter was identified on October 20, 2026.
On October 22, 2026, Kim left the audit committee; Wang Jo Cha joined it. The audit committee is now Stephen Markscheid, Umesh Patel and Wang Jo Cha.
As of the filing date, no Nasdaq notice had been received, and the units, Class A ordinary shares and rights continue to trade on Nasdaq.
On October 23, 2026, Idaho Copper Corporation filed a Preliminary Economic Assessment and NI 43-101 Technical Report under Canadian rules on SEDAR+ and posted it on its website. The company said it intends to file a revised version compliant with Subpart 1300 of Regulation S-K in the near future, which would be the document relevant to US disclosure standards.
Canadian PEA and NI 43-101 Technical Report filed on SEDAR+ on October 23, 2026
Company intends to file a revised US PEA compliant with Subpart 1300 of Regulation S-K via Form 8-K in the near future
Both versions are or will be available on the company's investor presentation page on its website
Greenwave Technology Solutions, Inc. set December 7, 2026 as the date of its 2026 annual meeting of stockholders and October 23, 2026 as the record date for stockholders eligible to vote. The date falls more than 30 calendar days from the anniversary of the prior year's meeting, and the filing sets deadlines of October 28 and November 2, 2026 for stockholder proposals. This is an administrative governance update with no direct financial impact.
2026 annual meeting set for December 7, 2026
Record date for voting eligibility is October 23, 2026
Stockholder proposals under Rule 14a-8 due by close of business October 28, 2026
Other stockholder business notices due by close of business November 2, 2026
Innventure, Inc. received a Nasdaq letter stating its common stock closed below the $1.00 minimum bid price for thirty consecutive business days ended October 22, 2026. The company has until April 21, 2027 to regain compliance, and the letter does not trigger immediate delisting, but there is no assurance the company will regain compliance or secure an additional compliance period.
Nasdaq notice dated October 23, 2026 cites the $1.00 minimum bid price requirement under Listing Rule 5450(a)(1).
Initial Compliance Period runs 180 calendar days, until April 21, 2027, requiring a closing bid of at least $1.00 for ten consecutive business days.
If not regained, the company may receive an additional 180 days by transferring its listing from the Nasdaq Global Market to the Nasdaq Capital Market and meeting other requirements.
The company states it is making diligent efforts to maintain its listing.
Andersons, Inc. said it eliminated the position of Executive Vice President and Chief Human Resources Officer Sarah J. Zibbel as part of a restructuring of its human resources department, with her employment ending October 31, 2026. The filing describes severance-related benefits and treatment of her equity awards, but it does not disclose financial figures for these payments.
Notice of position elimination given October 21, 2026; employment ends October 31, 2026
Ms. Zibbel is entitled to benefits under the Company's Change in Control & Severance policy for a qualifying termination
She keeps outstanding restricted stock units and a pro-rated portion of 2024 performance share units earned through the period ending in 2026
Her 2025 and 2026 performance share units will be forfeited
Climb Bio and Mabworks reported additional Phase 1 data in healthy volunteers for CLYM116/MIL116, an anti-APRIL antibody for IgA nephropathy, presented at ASN Kidney Week 2026. The data show an estimated half-life of about 33 days and, at 12 weeks after an 800 mg dose, reductions of about 70% in Gd-IgA1 and about 60% in IgA. The filing contains no revenue or earnings figures, and the next key milestone remains initial data from the NAVIGATE-2 Phase 2 trial in the first half of 2027.
Estimated half-life of approximately 33 days, based on the 800 mg and 320 mg multiple-ascending dose cohorts
Free APRIL suppression of 90% or more through 12 weeks after a single subcutaneous dose of 480 mg or higher
About 70% Gd-IgA1 and about 60% IgA reduction at 12 weeks after a single 800 mg dose, the NAVIGATE-2 loading dose
Injection site reactions in 5 of 88 participants, all Grade 1; initial NAVIGATE-2 data expected in the first half of 2027
On October 23, 2026, Edesa Biotech's board approved base salary increases for CEO Pardeep Nijhawan, President Michael Brooks and CFO Peter Weiler, effective retroactive to July 1, 2026. The filing says the executives' base salaries had last been adjusted in 2023. The filing does not state the total added cost, but the raises are a higher fixed compensation expense for shareholders to consider.
CEO Pardeep Nijhawan's base salary rises from $357,696 to $657,423.
President Michael Brooks's base salary rises from $335,340 to $591,681; CFO Peter Weiler's rises from $300,000 to $525,938.
Increases are retroactive to July 1, 2026; prior adjustments were made in 2023.
90% of Dr. Nijhawan's monthly base salary will continue to be paid in fully vested restricted share units under the 2019 Equity Incentive Compensation Plan.
22nd Century Group filed a prospectus supplement allowing it to sell up to $18.8 million of common stock under its at-the-market offering with Needham & Company, LLC. During October 2026, the company sold 15,785,757 shares for gross proceeds of about $4.7 million, and it had 19,202,198 shares outstanding as of October 23, 2026, so the sales are large relative to the existing share count and dilute current holders.
Prospectus supplement permits sales of up to $18.8 million of common stock under the Needham & Company, LLC sales agreement, filed October 23, 2026.
During October 2026, the company sold 15,785,757 shares for gross proceeds of about $4.7 million.
19,202,198 shares of common stock were outstanding as of October 23, 2026.
Exhibit 5.1 is an opinion of Foley & Lardner LLP, with a consent filed as Exhibit 23.1.
Azio AI Holdings entered an unsecured revolving credit agreement on October 21, 2026, with Azio Corporation, a lender whose CEO and majority shareholder is Chi Wei David Shiue, a former Chief Business Development Officer and sole member of a more-than-5% shareholder. The facility allows borrowing of up to $2.3 million, including $2.225 million of advances the lender had already provided, at 8.5% annual interest with a maturity one year after the effective date. The lender can terminate on 30 days' notice, which could make the funding less dependable for shareholders.
Credit commitment of up to $2,300,000, inclusive of $2,225,000 in prior advances from the lender
Promissory Note bears 8.5% annual interest; no interest or principal payments due before the maturity date
Maturity on the first business day after the one-year anniversary of the October 21, 2026 effective date
Lender may terminate on not less than 30 days' written notice; the Company may terminate on three days' notice after repaying all loans
Between October 20 and October 23, 2026, Tessera Defense issued 5,332,617 restricted shares to Mandragola Ltd. through cashless exercises of a warrant tied to its April 2026 acquisition of a 60% interest in Dr. Frucht Systems Ltd. At a October 20, 2026 Special Meeting, stockholders approved raising the shares reserved under the 2026 Equity Incentive Plan by 5,315,000 to 6,000,000, which adds potential dilution for existing holders.
Mandragola Ltd. received 5,332,617 restricted shares in three tranches between October 20 and October 23, 2026, from exercises of the DFSL Warrant issued April 13, 2026.
Proposal 1 passed at the October 20, 2026 Special Meeting with 3,540,463 votes for, 187,380 against and 591 abstaining.
The plan reserve rose from 685,000 to 6,000,000 shares, measured after the one-for-ten reverse stock split effective September 9, 2026.
The Company reported 25,995,794 shares outstanding as of October 23, 2026, compared with 9,026,478 entitled to vote at the October 5, 2026 record date.
AMASS Brands said its Chief Financial Officer, Zachary Ament, will resign effective November 16, 2026, and that Geoffrey McFarlane will serve as Interim Chief Financial Officer from November 17, 2026. The filing also reports a revised Series C Preferred Stock certificate that lowers the conversion price floor and a termination of a warrant held by Streeterville Capital, LLC.
CFO Zachary Ament resigned, effective November 16, 2026; the company said the resignation was not due to any disagreement on operations, policies, or financial disclosures.
Geoffrey McFarlane, age 43, was appointed Interim CFO effective November 17, 2026, while the board searches for a permanent CFO.
On October 22, 2026, the Series C Preferred Stock floor price was reduced from $4.00 to $1.00 per share.
The warrant to buy up to 3,500,000 common shares held by Streeterville Capital, LLC was terminated and cancelled, with no payment due from the company.
Traws Pharma entered a Common Stock Purchase Agreement with Roth Principal Investments, allowing the company to sell up to $50,000,000 of newly issued common stock over time at its own discretion. The company is under no obligation to sell any shares, and sales can begin only after a registration statement covering the resale of those shares is declared effective by the SEC.
Total commitment of up to $50,000,000 in newly issued common stock, at the company's option
Purchase price set at 94.0% of volume weighted average price, a fixed 6.0% discount, for market open, intraday, pre-market and post-market purchases
Sales require the closing price to be at least $0.10 (Threshold Price) and an effective registration statement; the period runs 36 months from the Commencement Date
Agreement dated October 23, 2026, with a related Registration Rights Agreement
Treasure Global's subsidiary Tadaa Technologies signed a Software Development Agreement on October 21, 2026, with Techcom Vintage Sdn Bhd to build a centralized fertilizer subsidy traceability and AI agriculture platform. Tadaa will pay fixed fees of RM8,000,000 in six milestone payments, and the Developer must deliver the platform in phases over about ten months from the effective date.
Fixed software development fees of RM8,000,000, with a mobilization payment of RM4,000,000 due within two business days after signing
Five delivery phases, with Phase 1 due within one month of October 21, 2026 and final integration due within ten months
Developer pays liquidated damages of 2% of a delayed phase's value per week, capped at 10%; Tadaa owns the resulting intellectual property
Medicus Pharma Ltd. said Nasdaq notified it on October 23, 2026 that it had regained compliance with the $1.00 minimum bid price requirement and that the matter is closed. The notice supersedes an October 20, 2026 delisting determination letter that would have removed the company's shares and warrants from The Nasdaq Capital Market. The company states there can be no assurance it will maintain compliance in the future.
Nasdaq notified the company on October 23, 2026 that it regained compliance with the $1.00 minimum bid price requirement.
The closing bid price was at or above $1.00 for ten consecutive business days, from October 12 to October 23, 2026.
An October 20, 2026 delisting determination letter was superseded and rendered moot by the compliance notice.
Earlier, Nasdaq had found the company ineligible for a second 180-day compliance period because it does not meet the minimum $5 million stockholders' equity requirement.
TeraWulf entered into an amendment to its existing revolving credit agreement with Morgan Stanley Senior Funding as administrative agent, increasing total commitments from $250 million to about $400 million as of October 23, 2026. The amendment also adds an uncommitted accordion feature of about $150 million and removes the $150 million sublimit for letters of credit, while allowing collateral release under certain conditions. The filing describes a larger, more flexible borrowing capacity, though it does not state how the company plans to use it.
Total revolving commitments rise from $250 million to about $400 million on the October 23, 2026 Effective Date.
An uncommitted accordion feature could add about $150 million more, subject to additional lender commitments and other conditions.
The $150 million sublimit on letters of credit is eliminated.
The amendment provides for release of collateral from the agent's security interest upon certain conditions; the full amended agreement will be filed with the Form 10-Q for the quarter ending September 30, 2026.
Silver Bow Mining and its subsidiary Silver Bow Tunnels amended their August 21, 2026 asset purchase agreement with Montana Goldfields and Montana Tunnels Mining, in an amendment dated October 20, 2026 and effective October 14, 2026. The changes set timing for the audited financial statements of Montana Tunnels Mining and for the shareholder approval process, which the company's proxy statement will seek. The filing does not state a purchase price or any financial results for the company.
Amendment is dated October 20, 2026, effective October 14, 2026, and amends the asset purchase agreement dated August 21, 2026.
Sellers will use reasonable efforts to deliver audited financial statements of Montana Tunnels Mining by October 31, 2026.
The Outside Date is now 60 days after the sellers deliver those audited financial statements.
The company will file a preliminary proxy statement within 5 business days after that delivery to seek shareholder approval, including approval of the CVRs and underlying common shares.
Alpine Income Property Trust filed agreements for at-the-market programs allowing it to sell up to $150 million of common stock and up to $35 million of Series A Preferred Stock, with sales made from time to time at prevailing market prices. The company also terminated its prior $35 million preferred program, under which about $22.7 million remained unsold, and its manager agreed to waive part of the base fee on equity raised from the preferred offering.
Common stock program: up to $150 million gross sales price, with sales agents including Raymond James, Baird, Stifel and UBS, and optional forward sale agreements.
Preferred program: up to $35 million of Series A Preferred Stock, replacing the December 2025 program, which had about $22.7 million unsold when terminated.
Sales agents receive commissions of up to 2.0% of gross sales price for shares they sell.
Manager waived part of the base fee on the added equity, so the rate on that portion is 0.75% per year instead of 1.50%; 189,747 more Series A Preferred shares were authorized, bringing the total to 3,948,081.
Expion Energy amended and restated its August 2026 private placement, under which it sold $9,000,000 of 8% convertible debentures and warrants. The debentures will now convert directly into common stock at $4.25 rather than into preferred stock that required stockholder approval, and the additional investment right is now a $91,000,000 debenture purchase option instead of preferred stock. The change affects potential dilution for shareholders, and the lead purchaser is linked to the company's former chief executive and chairman.
Original August 21, 2026 deal: $9,000,000 of 8% convertible debentures and warrants for up to 2,117,219 common shares
Amended October 22, 2026: debentures convert into common stock at an initial price of $4.25, subject to adjustment
Floor conversion price set at $0.72 per share; purchasers may buy up to $91,000,000 of additional convertible debentures within 18 months
Lead purchaser Five Narrow Lane, LP is linked to former CEO and Chairman Joseph Hammer; the deal was approved by disinterested directors
Transocean and Valaris filed a joint proxy statement on October 14, 2026 for shareholder votes on the planned Business Combination, under which Transocean would acquire all Valaris shares for 15.235 Transocean shares per Valaris share. Both shareholder meetings are scheduled for November 24, 2026, with a Bermuda court sanction hearing on November 26, and the companies expect the deal to close on or about December 1, 2026, if approvals are obtained.
Transocean and Valaris shareholder meetings are both scheduled for November 24, 2026.
Exchange ratio: 15.235 Transocean shares for each Valaris share.
Bermuda Supreme Court sanction hearing scheduled for Thursday, November 26, 2026.
Transocean expects the Business Combination to close on or about December 1, 2026, if conditions are met.
Cumberland Pharmaceuticals announced top-line results from its Phase 2a ASSIST-SSc trial of oral ifetroban in patients with systemic sclerosis, a rare disease. The company said the results support the drug's safety and tolerability in this population. The filing does not include efficacy data, financial figures, or guidance.
Trial: Phase 2a ASSIST-SSc evaluating oral ifetroban for systemic sclerosis
Announced October 23, 2026, with the press release furnished as Exhibit 99.1
Company states results support safety and tolerability of ifetroban in this rare disease population
Generic drugmaker BDR Pharmaceuticals has sued the FDA in federal court in Washington, D.C., challenging how the agency applied the GAIN Act to extend Phathom's new chemical entity exclusivity for VOQUEZNA tablets. If BDR succeeds, the exclusivity period could be shortened and generic versions could be approved earlier than Phathom currently expects.
BDR filed suit against the FDA in the U.S. District Court for the District of Columbia.
FDA recognized 10 years of NCE exclusivity for VOQUEZNA tablets through May 3, 2032, in a June 6, 2025 decision on Phathom's December 11, 2024 Citizen Petition.
Phathom says it is evaluating the filings and intends to take appropriate action to protect its statutory exclusivities.
Valaris and Transocean filed a joint proxy statement on October 14, 2026 for the planned Transocean acquisition of Valaris, under which each Valaris share would be exchanged for 15.235 Transocean shares. Valaris and Transocean shareholder meetings are scheduled for November 24, 2026, and a Bermuda court sanction hearing is set for November 26, 2026, with completion anticipated on or about December 1, 2026. The filing gives no financial results, and completion still depends on shareholder and court approvals and other conditions.
Exchange ratio: 15.235 Transocean shares for each Valaris share under a Bermuda scheme of arrangement
Valaris Court Meeting and Transocean Meeting both scheduled for November 24, 2026
Bermuda Supreme Court sanction hearing scheduled for November 26, 2026; closing anticipated on or about December 1, 2026
On October 19, 2026, a subsidiary of International Seaways agreed to become a subsidiary guarantor under its $500 Million revolving credit facility and to pledge one VLCC tanker as collateral. The tanker is a substitution vessel that replaces a collateral vessel sold in the third quarter of 2026. The filing describes a change to existing loan security rather than new borrowing, and it gives no financial results or amounts.
Joinder agreement dated October 19, 2026, under the Credit Agreement dated May 20, 2022, as amended through October 7, 2025
Subsidiary agreed to be bound as subsidiary guarantor and to pledge one VLCC tanker as collateral
The tanker replaces a collateral vessel sold and announced in the third quarter of 2026
Nordea Bank Abp, New York Branch, serves as administrative agent and collateral agent
Circle8 Group disclosed that its Lyneer subsidiary received a default notice from its professional employer organization, Employers Personnel, LLC, alleging missed payments under a service agreement. Separately, lender SPP Credit Advisors issued default notices under a financing agreement and a bridge loan, and senior lender SLR said it intends to sell substantially all Lyneer assets on or after October 27, 2026. The company disputes the validity of the asset sale notice and is reviewing the defaults, which could materially affect shareholders given the threatened asset sale.
PEO Employers Personnel, LLC alleged Lyneer is in default of payment obligations under its service agreement; discussions are ongoing.
SPP Credit Advisors letter dated October 14, 2026 asserted events of default under the Financing Agreement dated April 29, 2025 and the Bridge Loan Agreement dated June 18, 2024.
On October 15, 2026, Lyneer received notice that SLR intends to sell substantially all Lyneer assets under Article 9 of the UCC on or after October 27, 2026.
The company disputes the validity of the SLR notice and says it is reviewing the purported defaults in light of a Settlement Agreement dated August 7, 2026.
Art Technology Acquisition Corp. (ARTC) disclosed that director Walter T. Beach resigned from its board effective immediately on October 20, 2026. The company said the resignation was not due to any disagreement over its operations, policies or practices.
Walter T. Beach resigned as a board member on October 20, 2026, effective immediately.
The company states the resignation was not related to any disagreement on operations, policies or practices.
The filing was signed by CFO R. Maxwell Smeal and dated October 23, 2026.
On October 23, 2026, Fusemachines entered into an amendment with Meteora to its Shortfall Warrant, changing how the exercise price is set. The exercise price is now the average daily VWAP over the two trading days before a notice of exercise, and it is no longer tied to the Termination Price or a $0.85 minimum. The warrant now expires October 22, 2027 instead of October 22, 2028, and shareholders should note that the price is no longer subject to a floor.
Exercise price changed from the greater of the Termination Price under the Forward Purchase Agreement and $0.85 per share to the average daily VWAP for the two scheduled trading days before the notice of exercise date
Minimum exercise price no longer applies
Warrant expiration moved to 5:00 p.m. New York City time on October 22, 2027, from October 22, 2028
All other warrant terms remain in effect, per the filing
Darden Restaurants entered into a $1.5 billion amended and restated revolving credit agreement with Bank of America, N.A. as administrative agent, which replaces its prior $1.25 billion credit agreement. The company reported that no amounts were outstanding under the prior facility when it was terminated.
$1.5 billion senior unsecured revolving credit agreement dated October 22, 2026, maturing October 22, 2031
Replaces prior $1.25 billion credit agreement dated October 23, 2023, which had no amounts outstanding
Includes a $150 million letter of credit sublimit and a maximum consolidated net debt to total capitalization ratio of 3.50 to 1.00
Interest pricing depends in part on prevailing rates and the company's credit ratings
ARC Group Securities Acquisition I received a Nasdaq notice on October 20, 2026, saying its outstanding warrants no longer meet the $1 million minimum aggregate market value requirement. The notice is a deficiency warning, not an imminent delisting, and it has no current effect on trading of the warrants; the company plans to submit a compliance plan.
Nasdaq notice dated October 20, 2026; warrants fell below the $1 million aggregate market value minimum under Listing Rule 5452(b)(C)
Compliance plan due to Nasdaq by December 4, 2026
If the plan is accepted, Nasdaq may extend the compliance period to April 18, 2027
Notice affects only the warrants, not other securities, and does not currently affect their listing or trading
Acadia Pharmaceuticals said Elizabeth H.Z. Thompson, its Executive Vice President and Head of Research and Development, is retiring from her employee role effective October 23, 2026. She will remain with the company as a consultant, providing limited services through December 31, 2026, and the company is searching for a replacement.
Dr. Elizabeth H.Z. Thompson informed the company of her planned retirement on April 27, 2026, for personal reasons
Effective October 23, 2026, she no longer serves as an employee or as Head of Research and Development
She will be retained as a consultant and intends to provide limited consulting services through December 31, 2026
The company is in the process of identifying a replacement Head of Research and Development
Picard Medical, Inc. entered into an agreement on October 20, 2026, under which holders of warrants from its December 2025 private placement surrendered all of those warrants in exchange for 200,000 shares of common stock. The shares were issued October 22, 2026, and no cash changed hands, so the company received no proceeds. Shareholders should note the issuance adds 200,000 shares to the count and removes the warrants' anti-dilution rights.
Warrants were exercisable for 8,187,766 shares before the 1-for-50 reverse split effective July 31, 2026
Warrant Holders exchanged all Warrants for 200,000 shares of common stock; no cash exercise price was paid
Shares were issued October 22, 2026 under a Section 3(a)(9) exemption from registration
Warrants are cancelled, including anti-dilution and other adjustment rights; holders waive specified liquidated damages
Allegiant Air, a subsidiary of Allegiant Travel Company, exercised the first six options under its 2021 Boeing purchase agreement, with the six 737-8 aircraft scheduled for delivery in 2028, at a list price of more than $720 million before discounts and escalations. The company also entered into new employment agreements with four executive officers, including CEO Gregory Anderson, that run through the end of 2029.
Options for six 737-8 aircraft exercised; after this, the purchase agreement has 56 firm aircraft (22 delivered through October 23, 2026) and 74 remaining options.
List price of the six aircraft totals more than $720 million, subject to discounts and price escalations through delivery.
Agreements dated as of October 22, 2026 for Gregory Anderson (CEO, $750,000 base salary, 180% target cash bonus), Robert Neal (president and CFO, $525,000), and Drew Wells and Tyler Hollingsworth ($475,000 each).
All four employment agreements expire at the end of 2029; the Anderson agreement supersedes his 2024 agreement.
Energy Services of America completed its acquisition of substantially all operating assets of FAMCO, Inc., a West Virginia water and sewer utility contractor, for a base price of $6.95 million, subject to adjustments. The company says the acquired operations complement its existing water and utility construction business, and the filing does not report financial results for FAMCO.
Closed October 23, 2026 through subsidiary FAMCO Acquisition, Inc.
Base purchase price of $6.95 million, subject to adjustments; consideration is cash and Energy Services common stock
A portion of the purchase price is withheld pending a post-closing true-up
First Capital, Inc. (NASDAQ: FCAP) reported third-quarter 2026 net income of $5.1 million, or $1.53 per diluted share, up from $4.5 million, or $1.34, a year earlier. The tax-equivalent net interest margin rose to 4.08% from 3.71%, while the provision for credit losses increased to $355,000 from $150,000. For shareholders, quarterly and nine-month earnings per share both increased compared with 2025.
Q3 2026 net income was $5.1 million, or $1.53 per diluted share, versus $4.5 million, or $1.34, in Q3 2025.
Nine-month 2026 net income was $14.2 million, or $4.25 per diluted share, versus $11.5 million, or $3.43, a year earlier.
Tax-equivalent net interest margin was 4.08% for the quarter versus 3.71%; nonperforming assets rose to $5.5 million from $4.4 million at December 31, 2025.
Ardent Health said its Board found on October 19, 2026 that former CEO Martin J. Bonick failed to fully disclose third-party compensation, and recharacterized his June 2026 separation as a termination for Cause. The company will stop about $4.5 million of unpaid severance and cancel his unvested performance-based restricted stock units, and it reserved its rights to pursue other remedies. The filing says no financial statements or previously disclosed results need revision.
Bonick's employment as President and CEO and his board service ended effective June 2, 2026.
On October 19, 2026, the Board determined that facts discovered after the separation date would have supported a termination for Cause.
Ardent will discontinue about $4.5 million of unpaid cash severance and cancel or forfeit outstanding unvested PRSUs.
The company says none of its financial statements or previously disclosed results need to be revised or corrected.
Bank of America filed documents on October 23, 2026 for a new series of preferred stock, Series WW, with a 7.200% fixed-rate reset non-cumulative dividend and a $25,000 liquidation preference per share. The filing says the bank sold 2,000,000 depositary shares, each representing a 1/25th interest in a Series WW preferred share. Under the terms, dividend payments on common and junior stock would face restrictions if the bank fails to pay full dividends on Series WW.
Issued 80,000 shares of Series WW Preferred Stock on October 23, 2026
Series WW carries a 7.200% fixed-rate reset non-cumulative dividend and a $25,000 liquidation preference per share
Sold 2,000,000 depositary shares, each a 1/25th interest in a Series WW share, under an October 20, 2026 underwriting agreement
If full Series WW dividends are not paid, common stock dividends and buybacks face restrictions
On October 22, 2026, Tokeneke Road repaid in full the $5.0 million loan made by subsidiary BPOZ Tokeneke, paying $5,114,904.11 including $114,904.11 of accrued interest, and the convertible note was terminated with no early termination penalties. The payment was funded by a Related Party tied to the Chief Executive Officer's family, which received 352,753 Class A units of Tokeneke Partners and now holds about 71% of those units, and the Conflicts Committee and disinterested directors approved the prepayment.
Prepayment on October 22, 2026 totaled $5,114,904.11: $5,000,000 principal plus $114,904.11 accrued interest.
The note bore 3.6% annual interest, was due March 3, 2028, and could convert into Class A units at $14.50 per unit; the conversion right ended with the prepayment.
The Related Party contributed $5,114,918.50 to Tokeneke Partners for 352,753 Class A units at $14.50 per unit and now holds about 71% of outstanding units.
The Conflicts Committee and disinterested Board members approved the prepayment; the Company's letter agreement of January 6, 2026 was not affected.
Avidia Bancorp, Inc. reported third quarter 2026 net income of $8.6 million, or $0.47 per share, up from $7.2 million, or $0.39 per share, in the second quarter, and total net revenue rose 4% to $31.2 million. The company also declared a $0.06 per share quarterly cash dividend and said it had completed $23.8 million of share repurchases under a $30 million authorization as of September 30. The filing notes that net interest margin included a $692 thousand loan prepayment penalty.
Net income of $8.6 million ($0.47 per share) vs. $7.2 million ($0.39 per share) in the prior quarter; the company had a net loss of $907 thousand in the third quarter of 2025
Total net revenue of $31.2 million, up $1.3 million, or 4%, from the prior quarter
Quarterly dividend of $0.06 per share, payable on or about November 30, 2026, to holders of record on November 17, 2026
Share repurchases of $23.8 million completed as of September 30, 2026, against a $30 million authorization
Workday completed the sale of $2.5 billion of senior unsecured notes on October 23, 2026, under an underwritten offering agreed on October 21, 2026. The company estimates net proceeds of about $2.47 billion and plans to use $1.0 billion of them to retire its 3.500% notes due April 1, 2027, with any remainder for general corporate purposes. The new notes add $2.5 billion of debt with fixed interest rates from 5.700% to 6.500%, maturing between 2029 and 2036.
Four series totaling $2.5 billion: $750.0 million 5.700% due 2029, $500.0 million 6.000% due 2031, $750.0 million 6.300% due 2033, and $500.0 million 6.500% due 2036.
Estimated net proceeds of approximately $2.47 billion, after underwriting discount and offering expenses.
Use of proceeds includes retiring the $1.0 billion 3.500% notes due April 1, 2027; interest is payable semi-annually on April 23 and October 23, starting April 23, 2027.
Black Hawk Acquisition Corp deposited $150,000 into its trust account on October 22, 2026, extending the period it has to complete an initial business combination by one month, to November 22, 2026. The filing describes this as a routine extension of the company's deadline for a business combination, and it does not name a target or other deal terms.
Extension Payment of $150,000 deposited into trust account on October 22, 2026
Deadline to complete initial business combination extended one month, from October 22, 2026 to November 22, 2026
Filing does not name a business combination target
The Children's Place granted its Chief Financial Officer, John Szczepanski, a one-time cash retention award of $550,000 on October 19, 2026, under a letter agreement. The award vests on the six-month anniversary of the effective date if he remains employed in good standing, and he must repay it if he leaves or is terminated for cause before vesting.
One-time cash retention award of $550,000 granted to CFO John Szczepanski on October 19, 2026
Award vests on the six-month anniversary of the effective date, provided he remains employed in good standing
Repayment required if terminated for cause, or if he retires, resigns or otherwise leaves before vesting; not required if terminated without cause, subject to a release of claims
Full retention letter to be filed with the Form 10-Q for the quarter ending October 31, 2026
Iris Acquisition Corp II, a Cayman Islands blank-check company, issued an unsecured promissory note of up to $250,000 to listed payees on October 20, 2026, to fund expenses and general corporate purposes. The note is repayable only at a business combination or liquidation, and if repaid from trust funds or after a combination it carries an additional return of 150% or 250% of principal depending on timing.
Note principal of up to $250,000, bearing no stated interest rate, issued October 20, 2026.
Additional return of 150% of principal if a business combination closes on or before December 31, 2027; 250% if it closes after that date.
If no business combination is completed, the note is repaid only from amounts outside the trust account, if any.
Ribbon Acquisition Corp., a special purpose acquisition company, deposited $125,000 into its trust account for public shareholders on October 23, 2026. The payment extends the period the company has to complete its initial business combination by one month, from October 15, 2026 to November 15, 2026.
Extension Payment of $125,000 deposited into the trust account on October 23, 2026
Deadline to consummate initial business combination moved from October 15, 2026 to November 15, 2026
Filing is signed by Chief Executive Officer Angshuman (Bubai) Ghosh
XCF Global's subsidiary New Rise Renewables Paramount, LLC agreed on October 20, 2026 to buy a sustainable aviation fuel production facility in Paramount, California, from Air Products Manufacturing LLC, and will assume certain liabilities, including environmental liabilities. The price is $10 million in cash at closing plus an additional payment with a $50 million base amount, due 36 months after closing, and closing depends on customary conditions and insurance policies. XCF expects to invest about $30 million during a 9-12 month restart of the plant, and the filing gives no near-term financial results for the acquisition.
Agreement dated October 20, 2026 between New Rise Renewables Paramount, LLC (buyer), Air Products Manufacturing LLC (seller) and XCF Global, Inc.
Purchase price: $10 million cash at closing, plus an additional payment with a $50 million base amount due 36 months after closing.
Closing expected before the end of 2026; either party may terminate if closing has not occurred by December 15, 2026, subject to one 15-day extension.
XCF expects to invest about $30 million during the restart period, which it plans to complete over the next 9-12 months.
Methode Electronics said its Chief Accounting Officer and principal accounting officer, Stacie Schulz, will resign effective October 30, 2026, to pursue other opportunities. The company said the resignation is not due to any disagreement with its auditors or management on accounting or disclosure matters. CFO Laura Kowalchik will take on the principal accounting officer role, a change that is administrative in nature.
Stacie Schulz notified the company on October 19, 2026 of her decision to resign as Chief Accounting Officer.
The resignation takes effect October 30, 2026.
Laura Kowalchik, Chief Financial Officer, will also assume the principal accounting officer responsibilities.
The company states the resignation involved no disagreement with auditors or management on accounting or disclosure matters.
Dragonfly Energy Holdings received a Nasdaq extension, granted October 22, 2026, to regain compliance with the minimum stockholders' equity requirement, which its June 30, 2026 10-Q showed as a $(184,000) deficit against a $2.5 million minimum. The company must file a public report evidencing compliance by December 31, 2026, and failing that could face delisting, with a right to appeal to a Nasdaq hearings panel.
Stockholders' equity deficit of $(184,000) as of June 30, 2026, versus a $2.5 million minimum
Company submitted a compliance plan to Nasdaq staff on October 5, 2026
Nasdaq extension runs through December 31, 2026; compliance report is due on or before that date
If compliance is not evidenced, staff will issue written notice of delisting and the company may appeal
Alaunos Therapeutics said Nasdaq confirmed it has regained compliance with the $2,500,000 minimum stockholders' equity requirement, closing the matter and canceling the November 10, 2026 hearing before the Nasdaq Hearings Panel. Its common stock will continue to be listed and traded on The Nasdaq Capital Market, removing the near-term delisting risk for shareholders.
Nasdaq notified the company on April 9, 2026 that it was not in compliance with the $2,500,000 stockholders' equity requirement.
The company said a private placement completed on October 14, 2026 led it to believe it had regained compliance.
On October 22, 2026, Nasdaq's Office of General Counsel confirmed compliance and closed the matter.
The hearing scheduled for November 10, 2026 was cancelled.
Kingstone's Board of Directors declared a quarterly cash dividend of $0.06 per share, payable November 25, 2026 to stockholders of record at the close of business on November 11, 2026. The press release says this is the sixth consecutive quarterly dividend since the dividend was reinstated in July 2025, and the second at the $0.06 rate following a 20% increase approved in July 2026. The filing does not include financial results, so the announcement itself is the main news for shareholders.
Quarterly cash dividend of $0.06 per share declared
Record date: November 11, 2026; payment date: November 25, 2026
Sixth consecutive quarterly dividend since reinstatement in July 2025
Second payment at $0.06 rate, following a 20% increase approved in July 2026
The Trustee, Argent Trust Company, said SoftVest and other holders of more than 15% of the units requested a special meeting of unitholders on November 23, 2026. The proposals include approving an amendment to the Trust Indenture to effect a Business Combination under a Combination Agreement, approving the PBT Land and Minerals, Inc. Omnibus Incentive Plan, and authorizing a possible adjournment. The vote would decide whether the proposed transaction proceeds, which would affect unitholders' holdings.
Special meeting requested for November 23, 2026, with a record date of October 13, 2026.
Proposals cover a Trust Indenture amendment to effect the Business Combination, the Omnibus Incentive Plan, and a possible adjournment.
Trustee intends to call the meeting under the Indenture; notice to be mailed beginning October 23, 2026.
Trustee is not a party to the Combination Agreement and is not making a voting recommendation.
SiTime director Katherine E. Schuelke, a Class III director, notified the board on October 19, 2026 that she will resign from the board and two of its committees, effective October 20, 2026. The filing states her resignation was not due to any disagreement with the company or board, and the board reduced its size from nine to eight seats.
Katherine E. Schuelke resigns from the Board, Nominating and Corporate Governance Committee, and Compensation and Talent Committee, effective October 20, 2026
Resignation was not the result of a disagreement with the company or board on operations, policies, or practices
Board size reduced from nine to eight members, effective October 20, 2026
MarketAxess filed supplemental disclosures to its definitive proxy statement for its proposed merger with Intercontinental Exchange, which stockholders will vote on at a special meeting on October 29, 2026. The company made the additions to address three state court complaints and 15 stockholder demand letters alleging the proxy was incomplete or misleading, while denying the claims and saying no further disclosure is required.
Three stockholder complaints were filed in New York state courts between October 6 and October 15, 2026, seeking to block the merger until more disclosure is made.
As of October 23, 2026, the company had received 15 stockholder demand letters making similar allegations.
The filing discloses that on May 27, 2026, Intercontinental Exchange proposed $175.00 per share in cash, a premium of about 33.6% to the May 27 closing price of $130.94.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.